首页> 外文期刊>Clinical Pharmacology and Therapeutics >Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update
【24h】

Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update

机译:基于TPMT和NUDT15基因型的临床药疗法实施联盟指南硫孔给药:2018年更新

获取原文
获取原文并翻译 | 示例
           

摘要

Thiopurine methyltransferase (TPMT) activity exhibits a monogenic codominant inheritance and catabolizes thiopurines. TPMT variant alleles are associated with low enzyme activity and pronounced pharmacologic effects of thiopurines. Loss-of-function alleles in the NUDT15 gene are common in Asians and Hispanics and reduce the degradation of active thiopurine nucleotide metabolites, also predisposing to myelosuppression. We provide recommendations for adjusting starting doses of azathioprine, mercaptopurine, and thioguanine based on TPMT and NUDT15 genotypes (updates on ).
机译:硫嘌呤甲基转移酶(TPMT)活性表现出单一的Codominant遗传和分解硫嘌呤。 TPMT变异等位基因与低酶活性和硫嘌呤的明显药理学作用有关。 NUDT15基因的功能丧失等位基因在亚洲和西班牙裔中常见,减少活性硫嘌呤核苷酸代谢物的降解,也易于髓抑制抑制。 我们为根据TPMT和NUDT15基因型(更新)来提供调整Azathioprine,巯基嘌呤和Thioguanine的起始剂量的建议。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号